WO2003093292A1 - 17α-FLUORALKYL-11β-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN - Google Patents
17α-FLUORALKYL-11β-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN Download PDFInfo
- Publication number
- WO2003093292A1 WO2003093292A1 PCT/EP2003/004686 EP0304686W WO03093292A1 WO 2003093292 A1 WO2003093292 A1 WO 2003093292A1 EP 0304686 W EP0304686 W EP 0304686W WO 03093292 A1 WO03093292 A1 WO 03093292A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- benzaldehyde
- oxoestra
- oxime
- pentafluoroethyl
- dien
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Definitions
- the present invention relates to novel 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroids, a process for their preparation, pharmaceutical preparations containing these active substances and their use for the production of medicaments, in particular for postmenopausal substitution therapy for gynecological diseases such as uterine fibroids or dysmenoreal complaints.
- Anti-gestagenic steroids are already known from EP 0 057 115 A2. These can be 3-oxo-estra-4,9-dienes which are substituted in the 11-position.
- DE 43 32 283 A1 and DE 43 32 284 A1 describe 11 ⁇ -benzaldoxime-3-oxo-estra-4,9-diene derivatives which, according to DE 43 32 283 A1, are in the 17ß position with hydroxy, alkoxy, acyloxy or aryloxy and can be substituted in the 17 ⁇ position with ⁇ -fluoroalkyl.
- steroids with 17 ⁇ -fluoroalkyl chains are disclosed in DE 197 06 061 A1.
- ZK 230211 11 ⁇ - (4-acetylphenyl) -17ß- hydroxy-17 ⁇ - (1, 1, 2,2,2-pentafluoroethyl) estra-4,9-dien-3-one: U.Fuhrmann; H.Hess-Stumpp, A.CIeve, G.Neef, W.Schwede, J. Hoffmann, K.-H. Fritzemeier and K. Chwalisz: J. Med. Chem., 2000, 43, 5010-5016), show an almost pure antagonistic activity, high receptor selectivity and, inter alia, antiproliferative activity in tumor models.
- the object on which the present invention is based is to find active compounds with an antigestagenic activity which have a significantly reduced antiglucocorticoid activity compared to the known compounds and which are suitable for postmenopausal substitution therapy or for the treatment of gynecological diseases such as uterine fibroids or dysmenoric complaints.
- Another object on which the present invention is based is to find a process for the preparation of the active compounds.
- Another task is to find pharmaceutical preparations that contain the active ingredients.
- R. represents hydrogen, d- to C 6 -alkyl, COR ⁇ COOR 4) COSR 4 or CONHR 5 , in which R4 is C to C ⁇ -alkyl or unsubstituted or substituted aryl and in which R 5 is hydrogen, C to C ⁇ -alkyl or is unsubstituted or substituted aryl,
- R 2 represents hydrogen, Cr to C 6 alkyl or C to C 6 acyl
- any other substituents in particular alkyl and aryl groups, can be bonded instead of hydrogen.
- the present invention also relates to pharmaceutically acceptable salts of these compounds.
- Such acid addition salts can be salts of inorganic and organic acids, for example salts of hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, oxalic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid, salicylic acid, adipic acid and benzoic acid.
- Other acids that can be used are described, for example, in: Progress in Pharmaceutical Research, vol.
- the R ⁇ radicals mentioned in the present invention are in particular a hydrogen atom or a methyl group or acyl groups, such as, for example, formyl, acetyl, propionyl and benzoyl radicals, or carbonic acid ester groups, for example methoxycarbonyl or eth - Oxycarbonyl residues, or carbonic acid thiol ester groups, such as methylthiocarbonyl or ethylthiocarbonyl residues, or urethane groups, such as ethylaminocarbonyl or unsubstituted or substituted phenylaminocarbonyl residues.
- the substituted phenylaminocarbonyl radical is preferably substituted with ad- to Ce-perfluoroalkyl radical.
- R2 preferably represents a hydrogen atom, a methyl or an acetyl group.
- R 3 can be 1, 1, 1-trifluoromethyl, 1, 1, 2,2,2-pentafluoroethyl or 1, 1, 2,2,3 , 3,3-heptafluoropropyl are available.
- the compounds according to the invention are in particular the following 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroids:
- the compounds according to the invention are suitable for postmenopausal substitution therapy, also in combination with an estrogen, or can be used for the treatment of gynecological diseases such as uterine fibroids or dysmenoric complaints.
- the present invention also relates to a production process for the 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroids according to the invention.
- the 17 ⁇ -fluoroalkyl groups can be introduced into the steroid skeleton by starting from a 17-ketone according to methods known per se.
- Ruppert has described the production of trifluoromethyltrimethylsilane (Tetrahedron Letters, 1984, 25, 2195), which in the presence of tetrabutylammonium fluoride is ideally suited for introducing the trifluoromethyl group from aldehydes and ketones.
- R. Krishnamurti, DR Bellew, GKS Prakash, J. Org. Chem., 1991, 56, 984 and Lamberth, J. Prakt. Chem., 1996, 338, 586-587, Ruppert 's Reagent R. Krishnamurti, DR Bellew, GKS Prakash, J. Org. Chem., 1991, 56, 984 and Lamberth, J. Prakt. Chem., 1996, 338, 586-587, Ruppert 's Reagent).
- 17-ketones can be assumed for the introduction of the homologous fluoroalkyl groups into the steroid structure.
- processes have been described in which fluoroalkyl compounds with the general formula halogen-C n F 2n + ⁇ are reacted with metals to form organometallic compounds of the alkali or alkaline earth series with the general formula metal-C n F 2 n + ⁇ in situ. Latter can then be reacted with the 17-ketones to give 17 ⁇ -fluoroalkyl-17 ⁇ -hydroxy compounds. (DE 197 06 061 A1).
- the 17 ⁇ -fluoroalkoxymethyl grouping can preferably be introduced by a ring-opening reaction from a corresponding 17 (20) -spiroepoxide [Ponsold, Hübner, Schnabel, Stretch, Arzneistoff-Forschung (Drug Res.), 24 (1974) 896-900].
- R 3 , R 4 , R 6 , R 7 and R 8 have the meaning of the formula II in EP 0 411 733 A2 corresponding radicals R 3 , R 4 ' , R 6 , R 7 and R 8 have:
- the compound of the general formula II obtained by introducing the fluorinated alkyl group in the 17 ⁇ position with a salt of a hydroxylamine in a basic solvent, so that a 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroid is formed, in which R 1 is hydrogen, and then, if appropriate, to esterify, etherify or convert this compound into a corresponding carbamate, carbonic acid or thiocarbonic acid derivative.
- R 1 is hydrogen
- R 2 and R 3 in this general formula have the meanings given above.
- the salt of the hydroxylamine is preferably a hydrochloride or hydrosulfate.
- the basic solvent is preferably pyridine.
- the compound having the general formula II can, in an alternative embodiment of the invention, also be reacted with a compound having the general formula NH 2 -O-R 1 , in which R 1 has the abovementioned meaning.
- R 1 has the abovementioned meaning.
- the 17 ⁇ -fluoroalkyl-11 ⁇ -benzaldoxime steroids according to the invention are bound to the progesterone receptor (cf. Tab. 1) and, compared to RU 486, have (11ß- (4-dimethylaminophenyl) -17ß-hydroxy-17 ⁇ -propinyl-estra-4 , 9-dien-3-one) usually has a significantly reduced antiglucocorticoid effect, demonstrated by the reduced glucocorticoid receptor binding in vitro (see Table 1).
- N number of mated females
- N # number of non-gravid females
- the compounds according to the invention are suitable for postmenopausal substitution therapy and for the treatment of gynecological diseases, such as uterine fibroids, and for the treatment of dysmenoric complaints.
- the present invention also relates to medicinal substances (pharmaceutical preparations) for oral, rectal, subcutaneous, intravenous or intramuscular use, which together with conventional carriers and optionally diluents contain at least one compound having the general formula I as active ingredient.
- Medicaments according to the invention are produced with the customary solid or liquid carriers and / or diluents and the customarily generally used auxiliaries in accordance with the desired type of application in a suitable dosage and in a manner known per se.
- tablets, film-coated tablets, dragees, capsules, pills, powders, solutions or suspensions are preferably also prepared as a depot form.
- parenteral dosage forms such as injection solutions or suppositories should be considered.
- Pharmaceutical forms as tablets can be prepared, for example, by mixing the active ingredient with known auxiliaries, such as dextrose, sugar, sorbitol, mannitol, polyvinylpyrrolidone, disintegrants, such as corn starch or alginic acid, binders, such as starch or gelatin, lubricants, such as magnesium stearate or talc, and / or Agents that can achieve a depot effect, such as carboxypolymethylene, carboxymethyl cellulose, cellulose acetate phthalate or polyvinyl acetate, can be obtained.
- the tablets can also consist of several layers.
- Coated tablets can be prepared analogously by coating cores produced analogously to the tablets with agents commonly used in tablet coatings, for example polyvinylpyrrolidone or shellac, gum arabic, talc, titanium dioxide or sugar.
- the coated tablet case can also be made from consist of several layers, for example using the above-mentioned auxiliaries.
- the solutions or suspensions with the active ingredient according to the invention can be mixed with substances such as saccharin, cyclamate or sugar, and / or with flavorings such as vanillin or orange extract. Furthermore, they can be mixed with suspending aids, such as sodium carboxymethyl cellulose or preservatives, such as p-hydroxybenzoic acid.
- the capsules can be made by mixing the drug with carriers such as milk sugar or sorbitol, which are then placed in the capsules.
- Suppositories can preferably be produced by mixing the active ingredient with suitable carrier materials, such as neutral fats or polyethylene glycols or their derivatives.
- the galenical preparation contains the active substances in an amount of 1 to 100 mg, amounts in the range of 1,600 mg per day being required when used on humans.
- This compound is prepared from 4- [17 ⁇ -methoxy-17 ⁇ - (1,1,2,2,2-pentafluoroethyl) -3-oxoestra-4,9-dien-11 ⁇ -yl] benzaldehyde according to the procedure according to Example 2 made with hydroxylamine hydrochloride in pyridine.
- This compound is prepared according to Example 3 from 4- [17 ⁇ -methoxy-17 ⁇ - (1, 1, 2,2,2-pentafluoroethyl) -3-oxoestra-4,9-dien-11 ⁇ -yl] benzaldehyde- (1 U ) -oxime with 4-trifluoromethoxymethylphenyl isocyanate in toluene.
- reaction solution is decomposed by adding 10 ml of 1N HCl. Allow to come to room temperature, stir for 2 hours, cool again to 0 ° C and add another 0.5 ml of 1,1,2,2,3,3,3-heptafluoropropyltrimethylsilane. After 15 minutes the solution is hydrolyzed by adding 15 ml of 1N HCl. After a further 30 minutes, 100 ml of saturated ammonium chloride solution are added and the solution is extracted with ethyl acetate. The organic phase is washed neutral, dried over sodium sulfate, the organic phase is filtered off and concentrated under vacuum.
- the title compound is obtained from 4- [17 ⁇ -hydroxy-17 ⁇ - (1, 1, 2,2,3,3,3-heptafluoropropyl) -3-oxoestra-4,9-dien-11ß-yl] benzaldehyde by reaction prepared with hydroxylamine hydrochloride in pyridine according to Example 2.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004501431A JP2005536463A (ja) | 2002-05-03 | 2003-05-05 | 17α−フルオロアルキル−11β−ベンズアルドキシムステロイド、それらの製造方法、これらのステロイド類を含有する製剤及び医薬品製造のためのそれらの使用 |
| AU2003227717A AU2003227717A1 (en) | 2002-05-03 | 2003-05-05 | 17Alpha-FLUOROALKYL-11Beta-BENZALDOXIME-STEROIDS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING SAID STEROIDS AND THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS |
| AT03725149T ATE307823T1 (de) | 2002-05-03 | 2003-05-05 | 17a-fluoralkyl-11beta-benzaldoxim-steroide, verfahren zu deren herstellung, diese steroide enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln |
| DE50301507T DE50301507D1 (de) | 2002-05-03 | 2003-05-05 | 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN |
| EP03725149A EP1501859B1 (de) | 2002-05-03 | 2003-05-05 | 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10221034.9 | 2002-05-03 | ||
| DE10221034A DE10221034A1 (de) | 2002-05-03 | 2002-05-03 | 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US44940103P | 2003-02-25 | 2003-02-25 | |
| US60/449,401 | 2003-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003093292A1 true WO2003093292A1 (de) | 2003-11-13 |
Family
ID=29403591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2003/004686 Ceased WO2003093292A1 (de) | 2002-05-03 | 2003-05-05 | 17α-FLUORALKYL-11β-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1501859B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005536463A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE307823T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003227717A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE50301507D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1501859T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2252670T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003093292A1 (cg-RX-API-DMAC7.html) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011009532A2 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten |
| US8053426B2 (en) | 2006-11-15 | 2011-11-08 | Bayer Schering Pharma Ag | Progesterone receptor antagonists |
| US8278469B2 (en) | 2009-07-20 | 2012-10-02 | Bayer Pharma Aktiengesellschaft | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases |
| WO2013016725A1 (en) * | 2011-07-28 | 2013-01-31 | Evestra, Inc. | Progesterone antagonists |
| US9085603B2 (en) | 2010-02-10 | 2015-07-21 | Bayer Intellectual Property Gmbh | Progesterone receptor antagonists |
| US9096639B2 (en) | 2009-07-20 | 2015-08-04 | Bayer Intellectual Property Gmbh | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases |
| US9096640B2 (en) | 2009-07-20 | 2015-08-04 | Bayer Intellectual Property | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases |
| US9109004B2 (en) | 2010-02-10 | 2015-08-18 | Bayer Intellectual Property Gmbh | Progesterone receptor antagonists |
| US9206219B2 (en) | 2009-07-21 | 2015-12-08 | Bayer Intellectual Property Gmbh | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| EP0909764A1 (de) * | 1997-10-11 | 1999-04-21 | JENAPHARM GmbH | 11 Beta-Benzaldoxim-9 Alpha, 10 Alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
-
2003
- 2003-05-05 DE DE50301507T patent/DE50301507D1/de not_active Expired - Fee Related
- 2003-05-05 AT AT03725149T patent/ATE307823T1/de not_active IP Right Cessation
- 2003-05-05 EP EP03725149A patent/EP1501859B1/de not_active Expired - Lifetime
- 2003-05-05 ES ES03725149T patent/ES2252670T3/es not_active Expired - Lifetime
- 2003-05-05 DK DK03725149T patent/DK1501859T3/da active
- 2003-05-05 AU AU2003227717A patent/AU2003227717A1/en not_active Abandoned
- 2003-05-05 JP JP2004501431A patent/JP2005536463A/ja active Pending
- 2003-05-05 WO PCT/EP2003/004686 patent/WO2003093292A1/de not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| EP0909764A1 (de) * | 1997-10-11 | 1999-04-21 | JENAPHARM GmbH | 11 Beta-Benzaldoxim-9 Alpha, 10 Alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8053426B2 (en) | 2006-11-15 | 2011-11-08 | Bayer Schering Pharma Ag | Progesterone receptor antagonists |
| US9156877B2 (en) | 2009-07-20 | 2015-10-13 | Bayer Intellectual Property Gmbh | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases |
| WO2011009532A3 (de) * | 2009-07-20 | 2011-04-21 | Bayer Schering Pharma Aktiengesellschaft | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten |
| US8278469B2 (en) | 2009-07-20 | 2012-10-02 | Bayer Pharma Aktiengesellschaft | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases |
| US10155004B2 (en) | 2009-07-20 | 2018-12-18 | Bayer Intellectual Property Gmbh | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases |
| WO2011009532A2 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten |
| US9096639B2 (en) | 2009-07-20 | 2015-08-04 | Bayer Intellectual Property Gmbh | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases |
| US9096640B2 (en) | 2009-07-20 | 2015-08-04 | Bayer Intellectual Property | 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases |
| US9206219B2 (en) | 2009-07-21 | 2015-12-08 | Bayer Intellectual Property Gmbh | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases |
| US9085603B2 (en) | 2010-02-10 | 2015-07-21 | Bayer Intellectual Property Gmbh | Progesterone receptor antagonists |
| US9109004B2 (en) | 2010-02-10 | 2015-08-18 | Bayer Intellectual Property Gmbh | Progesterone receptor antagonists |
| CN103842370A (zh) * | 2011-07-28 | 2014-06-04 | 伊万斯彻有限公司 | 黄体酮拮抗剂 |
| WO2013016725A1 (en) * | 2011-07-28 | 2013-01-31 | Evestra, Inc. | Progesterone antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| DK1501859T3 (da) | 2006-03-06 |
| JP2005536463A (ja) | 2005-12-02 |
| EP1501859A1 (de) | 2005-02-02 |
| AU2003227717A1 (en) | 2003-11-17 |
| EP1501859B1 (de) | 2005-10-26 |
| DE50301507D1 (de) | 2005-12-01 |
| ATE307823T1 (de) | 2005-11-15 |
| ES2252670T3 (es) | 2006-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0648778B1 (de) | Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0254670B1 (de) | 11beta-(4-Isopropenylphenyl)-estra-4,9-diene, deren Herstellung und diese enthaltende pharmazeutische Präparate | |
| EP0299913B1 (de) | 11Beta-Phenyl-4,9,15-Estratriene, deren Herstellung und diese enthaltende pharmazeutische Präparate | |
| DE10221034A1 (de) | 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln | |
| EP1501859B1 (de) | 17a-FLUORALKYL-11BETA-BENZALDOXIM-STEROIDE, VERFAHREN ZU DEREN HERSTELLUNG, DIESE STEROIDE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE SOWIE DEREN VERWENDUNG ZUR HERSTELLUNG VON ARZNEIMITTELN | |
| EP1124841A1 (de) | Gallensauer substituierte phenyl-alkenoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikamente oder diagnostika sowie sie enthaltendes medika | |
| EP1060187A1 (de) | S-substituierte 11beta-benzaldoxim-estra-4,9-dien-kohlensäurethiolester, verfahren zu deren herstellung und diese verbindungen enthaltene pharmazeutische zubereitungen | |
| DE1493150A1 (de) | Verfahren zur Herstellung von tertiaeren Aminoalkyloximinoderivaten der OE?reihe | |
| CH651053A5 (de) | Steroid-zwischenprodukte. | |
| EP0909764A1 (de) | 11 Beta-Benzaldoxim-9 Alpha, 10 Alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate | |
| WO1992011279A1 (de) | D-HOMO-(16-EN)-11β-ARYL-4-ESTRENE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE DEREN VERWENDUNG ALS ARZNEIMITTEL | |
| WO1996008505A1 (de) | Steroidester und -amide, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung | |
| DE2759994C2 (de) | Ketale von 4-(1-Hydroxy-1-methylethyl)-3-cyclohexen-1-on und Verfahren zu ihrer Herstellung | |
| EP1237903A1 (de) | 11-beta-phenylestradien-derivate mit fluoralkylgruppen in der aromatischen seitenkette, deren herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| EP1090028B1 (de) | Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate | |
| DE2246462C3 (de) | 15 α , 16 α -Methylen-4-pregnene, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel | |
| DD289539A5 (de) | Verfahren zur herstellung von 11 beta-(4-acetylphenyl)-17alpha-alkoxy-methyl-estra-4,9-dien-3-onen | |
| AT233184B (de) | Verfahren zur Herstellung von 3-Oxo-Δ<1,4>-steroiden | |
| DE1958533C3 (de) | Verfahren zur Herstellung von 17 alpha-Propadienyl-Gruppen enthaltenden Steroiden | |
| DE3438500C1 (de) | Verfahren zur Herstellung 11ß-substituierter &Delta;&uarr;9&uarr;-19-Norsteroide | |
| DE1668124C3 (de) | 9 alpha-Unsubstitulerte 11 beta-ChIoM 9-norsteroide, Verfahren zu deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen | |
| DD299068A5 (de) | Verfahren zur herstellung von 11 beta-arylsubstituierten 17 beta-alkoxy-17 alpha -alkoxymethyl-estra-4,9-dien-3-onen | |
| DE102004019406A1 (de) | 17α-Fluorsteroide | |
| EP1658306A1 (de) | Delta 15 -d-homosteroide mit androgener wirkung | |
| CH433278A (de) | Verfahren zur Herstellung eines steroiden cyclischen Acetals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003725149 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004501431 Country of ref document: JP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003725149 Country of ref document: EP |
|
| WWG | Wipo information: grant in national office |
Ref document number: 2003725149 Country of ref document: EP |